Bosheng Qiu, MD
Internal Medicine · Alhambra, CANPI 1417096363
Payments from drug & device makers
Across 2,553 payments — averaging $112.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$98K
- Amgen$46K
- Amarin Pharma, Inc.$23K
- Boehringer Ingelheim$23K
- Gilead$17K
- Ironwood Pharmaceuticals, Inc$16K
- plus $64K from 54 others
What the payments were for
- Consulting fees$4,0201%
- Speaking & faculty fees$204,65872%
- Travel & lodging$8,1613%
- Food & beverage$68,85524%
- Education$3310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$286,025 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 1,167 | $677,365 |
| CreonLipase/Protease/Amylase | 280 | $458,465 |
| RybelsusSemaglutide | 379 | $385,458 |
| VascepaIcosapent Ethyl | 832 | $314,049 |
| LinzessLinaclotide | 521 | $268,840 |
| Icosapent Ethyl | 1,298 | $259,148 |
| Cyclosporine | 557 | $228,299 |
| KerendiaFinerenone | 327 | $208,811 |
| RestasisCyclosporine | 277 | $186,892 |
| EliquisApixaban | 384 | $146,600 |
| AfrezzaInsulin Regular, Human | 74 | $94,089 |
| TradjentaLinagliptin | 193 | $87,206 |
| JanuviaSitagliptin Phosphate | 166 | $83,990 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 118 | $81,738 |
| Memantine Hcl ErMemantine Hcl | 855 | $76,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis | $97,825 | $914,1981,078 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $22,619 | $782,2711,401 claims |
| Novo NordiskRybelsus, Ozempic | $1,951 | $413,304408 claims |
| BayerKerendia | $1,598 | $208,811327 claims |
| MerckJanuvia, Janumet | $2,723 | $150,273277 claims |
| PfizerEliquis | $1,203 | $146,600384 claims |
| AstraZenecaBreztri Aerosphere, Brilinta, Lokelma | $8,528 | $140,728218 claims |
| Mannkind CorporationAfrezza | $1,232 | $94,08974 claims |
| Johnson & JohnsonXarelto | $1,747 | $76,308131 claims |
| GSKTrelegy Ellipta | $3,224 | $56,33289 claims |
| GileadVemlidy | $16,678 | $49,91736 claims |
| Esperion Therapeutics, Inc.Nexletol | $1,746 | $46,473115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Alhambra
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.